However, in the Checkmate 141 trial (26), employing a threshold of ≥ 1% tumor membrane PD-L1 expression as the criterion for inclusion, nivolumab demonstrated a more pronounced reduction in mortality risk for PD-L1 positive patients compared to standard treatment, whereas PD-L1 negative patients exhibited a mortality risk ratio of 0.89 (95% CI: 0.54-1.45). The gene discussed is CD274; the disease is neoplasm.